Renal glucose reabsorption inhibitors to treat diabetes

被引：145

作者：

Bailey, Clifford J. ^{[1
]}

机构：

[1] Aston Univ, Birmingham B4 7ET, W Midlands, England

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2011年 / 32卷 / 02期

关键词：

INADEQUATE GLYCEMIC CONTROL; SELECTIVE SGLT2 INHIBITOR; INSULIN-RESISTANCE; DRUG-THERAPY; DOUBLE-BLIND; WEIGHT-GAIN; TYPE-2; DAPAGLIFLOZIN; METFORMIN; HYPERGLYCEMIA;

D O I：

10.1016/j.tips.2010.11.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Current therapies to reduce hyperglycaemia in type 2 diabetes mellitus (T2DM) mostly involve insulin-dependent mechanisms and lose their effectiveness as pancreatic beta-cell function declines. In the kidney, filtered glucose is reabsorbed mainly via the high-capacity, low-affinity sodium glucose cotransporter-2 (SGLT2) at the luminal surface of cells lining the first segment of the proximal tubules. Selective inhibitors of SGLT2 reduce glucose reabsorption causing excess glucose to be eliminated in the urine; this decreases plasma glucose. In T2DM, the glucosuria produced by SGLT2 inhibitors is associated with weight loss, and mild osmotic diuresis might assist a reduction in blood pressure. The mechanism is independent of insulin and carries a low risk of hypoglycaemia. This review examines the potential of SGLT2 inhibitors as a novel approach to the treatment of hyperglycaemia in T2DM.

引用

页码：63 / 71

页数：9

共 64 条

[1]

Abdul-Ghani Muhammad A, 2008, Endocr Pract, V14, P782

[2] Drug therapy - Metformin [J].

Bailey, CJ ;

Turner, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579

[3] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[4] Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].

Bakris, George L. ;

Fonseca, Vivian A. ;

Sharma, Kumar ;

Wright, Ernest M. .

KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277

[5]

Bays H, 2009, CURR MED RES OPIN, V25, P671, DOI [10.1185/03007990802710422, 10.1185/03007990802710422 ]

[6] Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin - Glucose and lipid effects [J].

Bays, Harold E. ;

Goldberg, Ronald B. ;

Truitt, Kenneth E. ;

Jones, Michael R. .

ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (18) :1975-1983

[7] Familial renal glucosuria:: SLC5A2 mutation analysis and evidence of salt-wasting [J].

Calado, J ;

Loeffler, J ;

Sakallioglu, O ;

Gok, F ;

Lhotta, K ;

Barata, J ;

Rueff, J .

KIDNEY INTERNATIONAL, 2006, 69 (05) :852-855

[8] Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion [J].

Calado, Joaquim ;

Sznajer, Yves ;

Metzger, Daniel ;

Rita, Ana ;

Hogan, Marie C. ;

Kattamis, Antonis ;

Scharf, Mauro ;

Tasic, Velibor ;

Greil, Johann ;

Brinkert, Florian ;

Kemper, Markus J. ;

Santer, Rene .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (12) :3874-3879

[9]

Chen J, 2008, DIABETES, V57, pA682

[10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

← 1 2 3 4 5 6 7 →